NovaBridge Biosciences (NASDAQ:NBP)
| Market Cap | 137.74M-75.9% |
| Revenue (ttm) | 0 |
| Net Income | -49.02M-28.3% |
| EPS | -0.58+19.6% |
| Shares Out | 50.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 583,220 |
| Open | 1.22 |
| Previous Close | 1.21 |
| Day's Range | 1.15 - 1.23 |
| 52-Week Range | 1.15 - 5.19 |
| Beta | 1.60 |
| Analysts | Buy |
| Price Target | 8.25(+590.38%) |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About NBP
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating NBP in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 12, 2026Earnings report
Ask Barron about NBP
$NBP stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in NBP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NBP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NBP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New NBP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NBP from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NBP
| ETF | Est. Holding Size |
|---|---|
| IBBiShares Biotechnology ETF | $791.22K |
| SPEMState Street SPDR Portfolio Emerging Markets ETF | $355.18K |
| SBIOALPS Medical Breakthroughs ETF | $165.59K |
| GXCState Street SPDR S&P China ETF | $18.01K |
| BIBProShares Ultra Nasdaq Biotechnology | $5.36K |
Estimated from each fund’s disclosed top holdings × AUM
NBP Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from NBP’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: 100 sector peers carry a ranked score; this one has no qualifying buying in the window · sector average 60.1
What’s Behind the Score
News check: Positive organizational strengthening (CFO appointment) and clinical trial progress (Phase 1b data supporting advancement) drive constructive outlook.
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 2Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.